Overview

ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Status:
Terminated
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
Phase:
Phase 2
Details
Lead Sponsor:
Immunovant Sciences GmbH